A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Ceritinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 19 Jul 2018 Planned End Date changed from 30 May 2018 to 12 Mar 2019.
- 19 Jul 2018 Planned primary completion date changed from 30 May 2018 to 12 Mar 2019.
- 19 Jul 2018 Status changed from recruiting to active, no longer recruiting.